David J. Mauro - 20 Jul 2021 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Chief Medical Officer
Signature
/s/ Brian Piper, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
20 Jul 2021
Transactions value $
$0
Form type
4
Filing time
22 Jul 2021, 18:13:00
Previous filing
08 Jul 2021
Next filing
09 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (Right to Buy) Award $0 +95K $0.00 95K 20 Jul 2021 Common Stock 95K $31.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.